Table 6.
Study name | Study groups with number of failures | Risk (R) | Risk ratio (RR) (95% CI) | P value | Interpretation of RR values |
---|---|---|---|---|---|
Bassat et al., 2009 [32] | DP (N/N): 143/1038 AL (n/N): 68/510 |
0.138 0.133 |
1.033 (0.790–1.352) |
0.811 | There was a marginal increase in treatment failure of 3.3% associated with DP treatment but it is not statistically significant. |
| |||||
Kamya et al., 2007 [30] | DP (n/N): 13/211 AL (n/N): 28/210 |
0.062 0.133 |
0.452 (0.245–0.867) |
0.016 | This result shows that DP treatment was associated with a point estimate reduction of 54.8% in treatment failure; with lowest and highest of the estimates being 13.3% and 75.5%, respectively, and it is statistically significant. |
| |||||
Sawa et al., 2013 [34] | DP (n/N): 0/134 AL (n/N): 4/145 |
0.000 0.028 |
0.120 (0.007–2.211) |
0.154 | DP treatment had contributed to 88% reduction in treatment failure but it is not statistically significant. The largest plausible reduction was 99.3%. |
| |||||
Yeka et al., 2008 [35] | DP (n/N): 5/215 AL (n/N): 13/199 |
0.023 0.065 |
0.356 (0.129–0.981) |
0.045 | This result is statistically significant. There was a reduction in failure in favour of DP treatment of 64.4%. The highest possible reduction was 87% and the lowest was 2% in favour of DP treatment of falciparum malaria. |